Our portfolio company Valink Therapeutics has announced a strategic partnership with Nona Biosciences to accelerate the development of bispecific antibody-drug conjugates (bsADCs), a promising class of precision cancer therapies.
The collaboration, branded "Biology to Bispecific" (B2B), combines Valink's LiliumX discovery platform with Nona's Harbour Mice technology for generating fully human antibodies. Traditional ADCs attach a cell-killing drug to an antibody that finds cancer cells. Bispecific ADCs recognize two different tumor markers, improving precision and potentially reducing side effects.
Read the full announcement here.
The collaboration, branded "Biology to Bispecific" (B2B), combines Valink's LiliumX discovery platform with Nona's Harbour Mice technology for generating fully human antibodies. Traditional ADCs attach a cell-killing drug to an antibody that finds cancer cells. Bispecific ADCs recognize two different tumor markers, improving precision and potentially reducing side effects.
Read the full announcement here.